94% identical to the body's own signal.

GLP-1 breaks down in about two minutes. Enzymes in the bloodstream find it, cut it apart, and clear it. The body recycles the pieces. The signal stops.

Scientists wanted GLP-1 to last longer. Staying longer would mean stronger effects and less frequent dosing. But signals aren't designed to last. It evolved to clear them quickly. That clearing is a feature, not a bug.

The engineering solution was elegant. Scientists changed specific amino acids and attached a C-18 fatty acid chain. Those edits help resist DPP-4 cleavage and support albumin binding, making the signal harder to clear.

That 6 percent difference includes amino acid substitutions and the fatty acid chain. Together, they block rapid destruction, help the molecule hitchhike on albumin, and stretch a two-minute signal toward seven days.

The 94 percent that stayed the same is crucial. The body recognizes semaglutide as GLP-1. It activates the same receptors. It reaches the same three stops in the brain. It produces the same effects on hunger, fullness, and reward.

But the 6 percent that differs changes everything about duration and strength. A seven-day hold means once-weekly dosing. Steady levels mean consistent effects.

Engineering matters. The body produces a perfect signal but clears it in two minutes. The system favors dynamic balance over permanent suppression. Engineering breaks that balance in one direction. Diet and exercise alone cannot replicate this.